Navigation Links
Once given 'no respect,' cells' tiny RNAS take driver's seat

Ribonucleic acid, or RNA, has long been thought to be important only to translate a gene's DNA into the proteins that are cells' workhorses. But new evidence shows that tiny bits of RNA not used to make proteins actually play central roles in normal biology and in the development of cancers.

"Scientists have known for a few years that production of these tiny RNAs, known as microRNAs, is only supposed to happen at certain times and in certain tissues, but no one had been able to identify what controlled the timing," says Joshua Mendell, M.D., Ph.D., assistant professor in the McKusick-Nathans Institute of Genetic Medicine. "We've identified the first such controller, a well-studied protein called Myc. Our discovery fits in quite well with the two other labs' studies on the involvement of microRNAs in cancer."

The work from investigators at Johns Hopkins is one of three papers on microRNAs in the June 9 issue of Nature.

Identified only a few years ago, microRNAs' best-known function is to control the extent to which other genes can be used to make proteins, by binding to and interfering with genes' protein building-instructions. The microRNAs play roles in cell division, cell specialization and cell death in worms and flies and are off-kilter in human cancers, but the Myc protein is the first factor identified that controls the production of microRNAs.

Myc (pronounced "mick") is already known to regulate about 10 percent to 15 percent of the genes in the human genome, controlling the extent to which they are used to make proteins. Myc also is faulty and overactive in many human cancer cells, although exactly how it contributes to cancer is unclear.

Given Myc's regulatory role and its involvement in cancer, the Hopkins researchers tested human cells to see whether changes in the amount of Myc affected levels of any of the more than 200 known microRNAs. Through these experiments and others, they discovered that Myc directly contro
'"/>

Source:Johns Hopkins Medical Institutions


Page: 1 2 3

Related biology news :

1. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
2. Fertility drugs given all-clear in new study
3. Experimental vaccine given during pregnancy reduces stillbirths from common virus
4. Two chemicals boost immune cells ability to fight HIV without gene therapy
5. How HIV disables the cells call for help
6. Stem cells electric abilities might help their safe clinical use
7. Scientists discover the molecular switch for nerve cells insulating jelly rolls
8. New insight into machinery of immune cells tentacles
9. Failure of scout cells may lead to cancer in transplant patients
10. Allergy cells can aggravate cancer and psoriasis
11. A key antibody, IgG, links cells capture and disposal of germs

Post Your Comments:
(Date:12/3/2009)...ies can be likened to emptying a museum of its col...dicines into the trash, or replacing every local c...e of species and their habitats may not just make ... also put you at greater risk for catching some na...sity loss,"driven by the replacement of local spec...
(Date:12/3/2009)... CTRC-AACR San Antonio Breast Cancer Symposium con...e and world leaders from industry and academia wit... year, more than 8,500 scientists and other profes...ntion Center in San Antonio from Dec. 9-13, 2009. ...n Association for Cancer Research, the University ...
(Date:12/3/2009)...ty change in warmer water, according to an intrigu...ake some species more aggressive. , Experiments ...s Great Barrier Reef have shown for the first time..., or consistently bold, and that these individual ...ures rise. , A slight lift of just one or two de...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Fish with attitude: Some like it hot 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Growth Attracts Additional Investors to Sittercity com 55841 1Growth Attracts Additional Investors to Sittercity com 55841 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2
...tin has received a six-year contract from the U.S....rt for the AN/UYQ-70 (Q-70) Advanced Display Syste... support at over $13 million a year for the first ...r the next four years, bringing the total potentia...t follows a recently awarded $525.6 million modifi...
...s March 19 during 12 p.m. Advertising Research Fou...e Research (R), a revolutionary media research fir... Advertising Research Foundation (ARF) conference ...identified key themes and styles that comprise imp...which were captured and delivered during the ARF,s...
...niversity of Florida have introduced ,Delicious, a...early, produces high yields, and is disease-resist...d texture with an edible skin, making it well-suit...or wine production. The name ,Delicious, was selec... sampled the fruit., According to Dr. Dennis J. Gr...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
(Date:12/2/2009)..., LIBREVILLE, Gabon, December 2 /PRNewswire/ -... Everyone,s Problem and Heritage" , Coinc... 2-3 June 2010 the,Gabonese Republic is hosting an... the issue of safeguarding biological resources in...ment and state leaders, ministers,scientific expe...
(Date:12/2/2009)... , CAMBRIDGE, Mass., Dec. 2 Te...aders in technology development and product integr...nounced the December 11th deadline for technology ... its 14th year, TechConnect World, in association ...TI), and the Clean Technology and Sustainable Indu...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)..., NANJING, China, Dec. 2 /PRNewswire-Asia/ -...Company") (NYSE: SCR ), a leading pharmaceutical...uring, and marketing of branded,generic and propri...at 105 of,its drugs have been included in China,s ...as issued by China,s Ministry of Human Resources a...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., R.I., May 28 Neurotech Pharmaceuticals, Inc. to..., NT-501, demonstrated a strong biologic effect ...ntosa (RP). RP is a slowly developing condition ...mp; cone photoreceptor cells in the retina that ov... eventually leads to blindness. RP is an orphan-de...
...NS, France, May 28 Poxel is a research integrated...ck Serono a division of,Merck KGaA, Germany, follo...est in diabetes research and development. It aims ...iseases (with a primary focus on Type 2,diabetes) ..., before,out-licensing these projects to major pha...
...rovides way of integrating and sustaining positive...28 In today,s uncertain times, increased stress c...rging wellness, growth and behavioral change parad...make healthier lifestyle choices and enjoy increas...llenges. , , The approach, called Reorganizationa...
Other Biology Technology:Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2
MitoPT-25:MITOCHONDRIAL PERMEABILITY TRANSITION KIT from AbD Serotec
Rabbit Anti-Human DDX5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Human phospho-RTKs Antibody array Assay Kit from R&D Systems
Human Antibody Array I Kit, RayBio L Series 507: RayBio Label-based from Raybiotech, Inc.
Biology Products: